ANXA1 and metabolic dysfunction-associated steatohepatitis: Altogether, these results afford a novel functional role for AnxA1 in NASH progression, a property mediated through a control of hepatic inflammation and fibrogenesis as well as uneven modulation of galectin-3 and IL-10, leading to a reduced macrophage M1 response.